Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

ADVANTIG-02: This Phase III trial is trying to understand effective different combinations of targeted and immunotherapies (Tislelizumab, Ociperlimab, and Pembrolizumab) are in people with non-small cell lung cancerA Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This is a randomised trial with three arms. In Arm A (Experimental), participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks. In Arm B (Active comparator), Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks. In Arm C (Placebo comparator), Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.

Treatment Type

Radiotherapy

Age

People 18+

Phase

III

Trial Acronym

ADVANTIG-02

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04746924
BEIGENE, BGB-A317-A1217-302, TIGIT-302, CT1363, BGB-302

Commercial Sponsor

BeiGene Australia Pty Ltd

Scientific Title

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.

Exclusion

You have been diagnosed with cancer, but have not received any treatment.
You have had a certain type of treatment or surgical procedure.
You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You have had treatment, but your cancer has come back.
Your cancer has not spread to other parts of the body.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Closed hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy